Biovail Corporation (TSE:BVF)

• Market Cap: $1.66B
• Enterprise Value: $1.38B
• Trailing P/E:  8.39
• Forward P/E (fye 31-Dec-10):  8.61
• Revenue (ttm):  $757.18M
• Gross Profit (ttm):  $560.01M
• EBITDA (ttm):  $329.78M
• Net Income Avl to Common (ttm):  $199.90M
• Diluted EPS (ttm): $1.25
• Trailing Annual Dividend Yield:  13.1%
• Payout Ratio:  90%
• Beta:  0.65

Its products include:
Xenazine — chorea associated with Huntington’s disease
Wellbutrin XL – depression in adults
Ultram ER — chronic pain in adults
Zovirax Ointment — management of initial genital herpes
Zovirax Cream — herpes labialis
Cardizem LA — blood pressure control
Tiazac/Tiazac XC — treatment of hypertension and angina
Wellbutrin SR — depression
Zyban — smoking cessation treatment
Monocor — hypertension and congestive heart failure
Retavase — tissue plasminogen activator used in thrombolytic therapy
Glumetza — hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes
Ralivia – management of pain
Nitoman — hyperkinetic movement disorders, such as Huntington’s chorea, Hemiballismus, Senile Chorea, Tic and Gilles de la Tourette Syndrome, and Tardive Dyskinesia

The Company is headquartered in Mississauga, Canada.